A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Key facts
- Who runs it
- Rutgers, The State University of New Jersey
- Where
- New Brunswick, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 1 Nov 2024
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- AN0025
- Record updated
- 16 April 2025
- Why it stopped
- The research was cancelled
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Be willing and able to provide written informed consent for the trial
- Age 18 years or greater
- Be fully active, able to carry on all pre-disease performance without restriction or restricted in physically strenuous activity but able to carry out work of a light or sedentary nature (e.g., light house work, office work)
- Be diagnosed with confirmed locally advanced and nonresectable, or metastatic Stage III Non-Small Cell Lung Cancer
- Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- Adequate staging of your disease
- Adequate lung function
- Adequate other organ functions
- No active second cancers
- Be willing and able to comply with all aspects of the protocol
- Female patients of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication
- Female participants of childbearing potential should be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
- Male participants should agree to abstinence or use of an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
Who cannot take part
- Have been discontinued in a prior treatment study with immunotherapy drugs due to a severe toxicity (Grade 3 or higher)
- Received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed
- Had an allogenic tissue/solid organ transplant
- A diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to the first dose of study drug
- Major surgery within four weeks before the first dose of study drug
- Known active cancer spread to central nervous system
- Known severe hypersensitivity to study treatment components
- An active autoimmune disease that has required systemic treatment in the past two years
- Have inflammatory bowel disease
- Have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis
- Have a history of interstitial lung disease
- Have an active infection requiring systemic therapy
- Have human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections,
- Significant cardiovascular impairment: history of congestive heart failure, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia
- Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting)
- Have a known psychiatric or substance abuse problems
- Have abnormal electrocardiogram (Prolongation of QT interval)
- Age less than 18 years
- Weight less than 30 Kg (~66 lbs)
- Pregnant or breastfeeding women
Where in United States
- Rutgers Cancer Institute of New JerseyNew Brunswick, United States
About the trial
What the trial wants to find out
Primary
Read full original descriptionShow less
* Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) * Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory * Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab
The 2 groups in the trial
- AN0025: Dose level one: 250 mg dailyTreatment being tested
Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
Treatment: AN0025
- AN0025: Dose level two: 375 mg dailyTreatment being tested
Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
Treatment: AN0025
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 April 2025